NASDAQ:ORKA Oruka Therapeutics Q1 2025 Earnings Results & Report $78.19 -2.16 (-2.69%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$78.50 +0.31 (+0.40%) As of 10/13/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Oruka Therapeutics beat analyst earnings expectations in its Q1 2025 results, released August 11, 2025. The company reported EPS of -$0.46 versus the -$0.48 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateAugust 11, 2025TimeBefore Market Opens Oruka Therapeutics EPS ResultsActual EPS-$0.46Consensus EPS -$0.48Beat/MissBeat by +$0.02One Year Ago EPSN/AEPS Beat Rate6 of last 7 quartersOruka Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsOruka Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Oruka Therapeutics Q1 2025 Earnings FAQ Did Oruka Therapeutics beat earnings estimates for Q1 2025? Oruka Therapeutics (NASDAQ:ORKA) reported earnings of -$0.46 per share for Q1 2025, beating the consensus estimate of -$0.48. The report was announced on Monday, August 11, 2025. When is Oruka Therapeutics' next earnings date? Oruka Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Oruka Therapeutics on the company's earnings history page. Oruka Therapeutics Earnings HeadlinesORKA-002 Phase 1 Milestone: What Oruka’s First-in-Human Trial Means for InvestorsOctober 9, 2026 | tipranks.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Has Consensus Target Price of $128.91October 8, 2026 | americanbankingnews.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters. | Paradigm Press (Ad)Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 25,000 Shares of StockOctober 3, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Co-Diagnostics (CODX)September 25, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)September 24, 2026 | theglobeandmail.comSee More Oruka Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email. Email Address About Oruka TherapeuticsOruka Therapeutics (NASDAQ:ORKA) (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions. Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases. The programs are being developed initially for conditions such as plaque psoriasis, with potential applications in other immune-mediated disorders. Oruka became a publicly traded company through a business combination with ARCA biopharma, Inc. in 2024, after which ARCA adopted the Oruka Therapeutics name and its shares began trading under the ORKA symbol. The company is focused on advancing its pipeline through clinical development and regulatory processes for patients in the United States and potentially other markets.View Oruka Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
